EMA Authorised: Celsunax (ioflupane (123i)) — Pinax Pharma GmbH

View source ↗

Summary

EMA authorised Celsunax (ioflupane (123I)) by Pinax Pharma GmbH for radionuclide imaging to aid the assessment of movement disorders and dementia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia
• Dementia with Lewy Bodies
• Essential Tremor
• Parkinson Disease

Drugs mentioned

• Celsunax (ioflupane (123I))

Snippet

Status: Authorised. Therapeutic area: Radionuclide Imaging;Dementia;Movement Disorders. MAH: Pinax Pharma GmbH. Decision date: 14/11/2024